• High binding affinity • Distinct epitopes from several clinical anti-TIGIT antibodies, including Tiragolumab• • Potent blockade of hCD155 (hPVR) binding • Capable of FcγIIIA-mediated signaling in reporter cells in IgG1 format • Superior in vivo anti-tumor activity in syngeneic model • Excellent stability under stressful conditions, making them good candidates for development